Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Shares Rise 9 Percent

Shares of Bruker BioSciences climbed 9.1 percent for the five-day trading week ended Tuesday, leading all gainers in the BCW Index. The only other stock in the Index to gain more than 5 percent for the week was that of Illumina, which rose 5.4 percent.
 
Caliper Life Sciences led decliners for the week, dropping 6.6 percent.
 
Overall, the Index gained 1.1 percent. In comparison, the Dow Jones Industrial Average fell 1 percent, the Nasdaq declined 1.2 percent, and the Nasdaq Biotech Index gained 1.2 percent.

 
 
BioCommerce Week Index of Diversified
Molecular Biology Tool Companies
Company
Ticker
Closing Price
(Sept. 11, 2007)
Starting Price
(
Sept. 4, 2007)
% change
Affymetrix
AFFX
23.41
23.51
-0.43
Agilent
A
36.31
36.4
-0.25
Applied Biosystems
ABI
32.1
32.23
-0.40
Beckman
BEC
72.25
72.02
0.32
Becton Dickinson
BDX
77.71
77.02
0.90
Bio-Rad
BIO
85.56
85.67
-0.13
Bruker
BRKR
7.68
7.04
9.09
Caliper
CALP
5.41
5.79
-6.56
Cepheid
CPHD
20.01
20.17
-0.79
Illumina
ILMN
51.43
48.78
5.43
Invitrogen
IVGN
81.52
79.1
3.06
Luminex
LMNX
14.99
14.45
3.74
MDS
MDZ
20.69
19.87
4.13
Millipore
MIL
73.63
71.89
2.42
PerkinElmer
PKI
27.42
27.48
-0.22
Qiagen
QGEN
17.11
17.12
-0.06
Sequenom
SQNM
5.05
5.07
-0.39
Sigma-Aldrich
SIAL
43.86
44.9
-2.32
Thermo
TMO
54.5
54.54
-0.07
Third Wave
TWTI
8.11
7.75
4.65
Waters
WAT
63.62
62.44
1.89
BCW Index Average  
39.16
38.73
1.12
The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more